DM
ANTX icon

Deerfield Management’s AN2 Therapeutics ANTX Stock Holding History

Deerfield Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-716,538
Closed -$12.5M – 106
2022
Q3 		$12.5M Hold
716,538
– – 0.25% 75
2022
Q2 		$5.55M Buy
716,538
+132,402
+23% +$1.75M 0.11% 92
2022
Q1 		$8.8M Buy
+584,136
New +$8.86M 0.2% 76

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Deerfield Management's ANTX Position: Q4 2022 in Review

Deerfield Management sold out of AN2 Therapeutics (ANTX) in Q4 2022, closing a stake of 716,538 shares — an estimated $12.5M sold.

Deerfield Management first reported a position in ANTX in Q1 2022 and held it in 3 quarters. The position peaked at $12.5M in Q3 2022. 36 funds tracked by Wall St. Rank hold ANTX as of Q4 2022.

  • Deerfield Management reported no remaining AN2 Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Deerfield Management sold 716,538 AN2 Therapeutics shares in Q4 2022, an estimated $12.5M.
  • Deerfield Management first reported a position in AN2 Therapeutics in Q1 2022 and held it in 3 quarters.
  • Deerfield Management's AN2 Therapeutics position peaked at $12.5M in Q3 2022.
  • 36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2022.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.